@article{45fbf9ce68f34b689d30a3f95bb7be55,
title = "DCC mutation update: Congenital mirror movements, isolated agenesis of the corpus callosum, and developmental split brain syndrome",
abstract = "The deleted in colorectal cancer (DCC) gene encodes the netrin-1 (NTN1) receptor DCC, a transmembrane protein required for the guidance of commissural axons. Germline DCC mutations disrupt the development of predominantly commissural tracts in the central nervous system (CNS) and cause a spectrum of neurological disorders. Monoallelic, missense, and predicted loss-of-function DCC mutations cause congenital mirror movements, isolated agenesis of the corpus callosum (ACC), or both. Biallelic, predicted loss-of-function DCC mutations cause developmental split brain syndrome (DSBS). Although the underlying molecular mechanisms leading to disease remain poorly understood, they are thought to stem from reduced or perturbed NTN1 signaling. Here, we review the 26 reported DCC mutations associated with abnormal CNS development in humans, including 14 missense and 12 predicted loss-of-function mutations, and discuss their associated clinical characteristics and diagnostic features. We provide an update on the observed genotype–phenotype relationships of congenital mirror movements, isolated ACC and DSBS, and correlate this to our current understanding of the biological function of DCC in the development of the CNS. All mutations and their associated phenotypes were deposited into a locus-specific LOVD (https://databases.lovd.nl/shared/genes/DCC).",
keywords = "ACC, DCC, NTN1, Netrin-1, agenesis of the corpus callosum, axon guidance, developmental split brain syndrome, horizontal gaze palsy with progressive scoliosis, mirror movements, mutation",
author = "{IRC5 Consortium} and Marsh, {Ashley P.L.} and Edwards, {Timothy J.} and Charles Galea and Cooper, {Helen M.} and Engle, {Elizabeth C.} and Jamuar, {Saumya S.} and Aur{\'e}lie M{\'e}neret and Moutard, {Marie Laure} and Caroline Nava and Agn{\`e}s Rastetter and Gail Robinson and Guy Rouleau and Emmanuel Roze and Megan Spencer-Smith and Oriane Trouillard and {Billette de Villemeur}, Thierry and Walsh, {Christopher A.} and Yu, {Timothy W.} and Delphine Heron and Sherr, {Elliott H.} and Richards, {Linda J.} and Christel Depienne and Leventer, {Richard J.} and Lockhart, {Paul J.}",
note = "Funding Information: A.M. received travel funding from Zambon Company and AbbVie Funding Information: Aguettant, IP Sant{\'e}, Ultragenix, IPSEN, Association Fran{\c c}aise pour l'H{\'e}mipl{\'e}gie Alternante, AMADYS; served on scientific advisory boards for Orkyn, Ultragenix, Retrophin, and Merz Pharma; received speech honoraria from Orkyn, Aguettant, Merz Pharma, and Ultra-genix; and received travel funding from the Dystonia Coalition, the Dystonia Medical Research Foundation, the Movement Disorders Society, and the European Academy of Neurology. S.S.J. is co-founder of Global Gene Corporation. T.W.Y. is co-founder of and part-time consultant to Claritas Genomics. Funding Information: Contract Grant Sponsors: National Health and Medical Research Council (NHMRC) Australia (GNT1059666, GNT1126153, GNT1032364); Campbell Edwards Trust; Victorian Government's Operational Infrastructure Support Program; Australian Government NHMRC IRIISS; Boston Children's Hospital; National Institutes of Health IDDRC (1U54 HD090255); Australian Postgraduate Award; University of Queensland Research Scholarship; Thierry and Annick Desmarest Foundation. Funding Information: The authors gratefully acknowledge the participation of the patients and their families in these studies and the support of the Australian Disorders of the Corpus Callosum (AusDoCC) organization, as well as the generous financial support of the Lefroy and Handbury families. The authors also acknowledge and thank Ivo Fokkema and Johan T. den Dunnen from the Leiden University Medical Center for their assistance in establishing the DCC LOVD. Funding Information: The authors gratefully acknowledge the participation of the patients and their families in these studies and the support of the Australian Disorders of the Corpus Callosum (AusDoCC) organization, as well as the generous financial support of the Lefroy and Handbury families. The authors also acknowledge and thank Ivo Fokkema and Johan T. den Dunnen from the Leiden University Medical Center for their assistance in establishing the DCC LOVD. A.M. received travel funding from Zambon Company and AbbVie Inc. E.R. has received research support from Merz-Pharma, Orkyn, Aguettant, IP Sant?, Ultragenix, IPSEN, Association Fran?aise pour l'H?mipl?gie Alternante, AMADYS; served on scientific advisory boards for Orkyn, Ultragenix, Retrophin, and Merz Pharma; received speech honoraria from Orkyn, Aguettant, Merz Pharma, and Ultragenix; and received travel funding from the Dystonia Coalition, the Dystonia Medical Research Foundation, the Movement Disorders Society, and the European Academy of Neurology. S.S.J. is co-founder of Global Gene Corporation. T.W.Y. is co-founder of and part-time consultant to Claritas Genomics. Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2018",
month = jan,
doi = "10.1002/humu.23361",
language = "English",
volume = "39",
pages = "23--39",
journal = "Human mutation",
issn = "1059-7794",
number = "1",
}